18 July 2023
The experimental drug donanemab slows the progression of Alzheimer's disease compared with a placebo, but the effect may not be large enough to be noticed by people with the condition or their families
24 May 2023
Antibody treatments that target amyloid plaques in the brains of people with Alzheimer's have shown promise in trials, but questions about their side effects and practicality remain
15 May 2023
Researchers have identified two people from the same Colombian community with genes that both promote and prevent early onset Alzheimer's disease - a discovery that could lead to new treatments
4 May 2023
The experimental treatment donanemab is now the second antibody drug to slow cognitive decline in people with early stage Alzheimer’s disease, but questions remain about its real-world benefits and safety
30 March 2023
A fluid-filled network that clears waste products from the brain may be important in neurological conditions, but we know little about how it works
8 March 2023
A “grand unifying theory” of brain ageing suggests malfunctioning mitochondria might be to blame for Alzheimer’s and other brain conditions. And this new avenue of exploration already has some potential therapies at the ready
18 January 2023
There are many things we can do to try to reduce our risk of dementia, but the condition is not usually preventable
12 December 2022
Removing only a small segment of a gene in the brain cells of mice reduced the formation of plaques seen in Alzheimer’s disease by 44 per cent
30 November 2022
The drug lecanemab slowed the rate of cognitive decline among people with early Alzheimer's disease by 27 per cent, compared with placebo infusions, but some question if its potential safety concerns outweigh any benefits
16 November 2022
Kynurenic acid is made in the brain and could play a role in psychosis related to schizophrenia, Alzheimer’s disease and bipolar disorder – and new drugs may be able to reduce it
